Mounjaro®
Starting from £179.99/mo
Start journey Learn moreOlder adults asking about Wegovy for seniors will find the same licensed eligibility criteria apply regardless of age: adults with a BMI of 30 or above, or 27 or above with a weight-related health condition, may be considered for semaglutide (Wegovy) following a full clinical assessment by a prescriber. Age itself is not a barrier, but it does shape how treatment is approached. Muscle preservation, existing medicines, slower kidney function and bone health all come into the conversation when a prescriber reviews someone in their 60s, 70s or beyond. These are questions worth understanding before you start — and this page works through them honestly, step by step.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The starting point is always a clinical assessment, not a tick-box. For older adults, that assessment carries more weight than usual. Wegovy is licensed for adults with a BMI of 30 or above, or from 27 upwards if a weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol, obstructive sleep apnoea or osteoarthritis is present. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. The prescriber at our clinical team will look beyond those numbers, though.
Kidney function tends to decline gradually with age, and because Wegovy is cleared partly via the kidneys, the prescriber considers how well yours are working. Heart conditions, history of pancreatitis, and any active gallbladder problems are all reviewed. Older adults also typically take more regular medicines (antihypertensives, statins, thyroid medications, blood thinners) and semaglutide's slowing of gastric emptying can shift how quickly some of those are absorbed. That is not a reason to rule out treatment; it is a reason to be thorough upfront. You can read about the broader eligibility picture on the is Wegovy right for me page, which covers the full criteria in plain terms.
At nume, every consultation is read personally by a GPhC-registered Independent Prescriber. A real clinician works through your answers the same day, there is no automated decision. That matters here because the nuance in an older adult's health history is exactly what an algorithm would miss.
Wegovy begins at 0.25 mg once weekly and increases in stages, typically every four weeks, up to the 2.4 mg maintenance dose. The MHRA has also approved a 7.2 mg maintenance dose, available as a dedicated single-dose pen since April 2026, though your prescriber determines which dose is appropriate and confirms availability at the point of assessment. Each pen is colour-coded by dose to make identification straightforward, and you can read about the Wegovy colours and what each one represents if you want to know what to expect in the box. The gradual titration exists because the gastrointestinal side effects (nausea, loose stools, reduced appetite) tend to be most pronounced in the first weeks and soften as the body adjusts. For older adults, that adjustment period deserves extra patience.
Nausea that reduces food intake significantly can accelerate muscle loss if protein intake drops too low. Staying well hydrated matters more too: older adults are at higher baseline risk of dehydration, and GI side effects compound that. The NHS guidance on weight-management injections published by NHS England highlights the importance of dietary support running alongside treatment, something worth discussing with both your prescriber and, where available, a dietitian.
For those curious about how long treatment typically runs, the question of whether Wegovy is for life is worth reading; it explains what the evidence says about maintenance and what happens when people stop.
The side-effect profile of semaglutide is led by the gut: nausea, constipation, reflux and reduced appetite are the most commonly reported effects in clinical trials and in practice. These are typically temporary and ease after the first few weeks or following a dose increase. For older adults, a few deserve particular attention.
The MHRA's Yellow Card scheme allows patients and carers to report suspected side effects directly, and doing so helps regulators monitor safety in real-world populations including older adults. If you experience severe or persistent stomach pain that reaches through to your back, seek medical help promptly, this can be a sign of pancreatitis, which, while uncommon, is a known risk with GLP-1 medicines.
Falls risk is rarely discussed in Wegovy conversations, but it is relevant for seniors. Dizziness is listed as a potential side effect, and significant weight loss can shift balance and gait. If you notice lightheadedness (especially around changes in blood pressure medication) raise it with your prescriber before the next dose. Bone density is another longer-term consideration: rapid weight loss can reduce bone mineral density, and older adults, particularly postmenopausal women, have less reserve to draw on. Strength-bearing activity and adequate calcium and vitamin D intake are worth factoring into your wider plan.
Symptoms that need prompt medical attention include severe stomach pain, signs of dehydration (dizziness, dark urine, very little urine output), gallbladder pain (sharp pain in the upper right abdomen), and any signs of an allergic reaction. Aftercare at nume runs seven days a week, if something feels off between consultations, our support team can help you decide what to do next.
Through the NHS, Wegovy is available via specialist weight management services under NICE guidance (TA875), which requires a BMI of 35 or above alongside at least one weight-related comorbidity, and limits treatment to a maximum of two years within a multidisciplinary service. Waiting lists for those services are commonly long. Many older adults find they meet the clinical criteria but simply cannot access treatment in a reasonable timeframe through the NHS. Private treatment through a regulated online pharmacy is the practical alternative for that group.
It is worth knowing that cost discussions around weight-loss medicines sometimes focus on finding the lowest monthly price. For older adults on multiple medications, the quality of clinical oversight matters considerably more than the headline figure. Our Wegovy cost and NHS access page explains what free NHS treatment requires and what private routes involve. Treatment pricing through nume is shown clearly on our treatments page, and includes consultation, prescription and next-working-day delivery in a single transparent figure, no subscription, no hidden charges. If your order is placed on a Monday before noon, your prescription is reviewed that same day and dispatched for next-day delivery, which lines up neatly if you plan ahead at the start of the week.
If you want a fuller picture of how semaglutide works before deciding anything, the semaglutide overview covers the mechanism and evidence in depth. And if you are specifically wondering whether there is a formal upper age limit, the Wegovy age limit page addresses that directly.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.